Table 2. Baseline Characteristics Among Treatment Groups After Propensity Score Matchinga.
| Characteristics | No. (%) | SMDb | |||
|---|---|---|---|---|---|
| Neoadjuvant | Surgery alone | Adjuvant | Neoadjuvant vs adjuvant | Neoadjuvant vs surgery alone | |
| No. (%) | 101 (14.3) | 303 (42.9) | 303 (42.9) | NA | NA |
| Age, median (IQR), y | 59 (36-87) | 59 (21-87) | 60 (31-83) | −0.07 | −0.02 |
| Sex | |||||
| Male | 32 (14.5) | 99 (44.8) | 90 (40.7) | −0.02 | 0.01 |
| Female | 69 (14.2) | 204 (42.0) | 213 (43.8) | ||
| Race and ethnicity | |||||
| Hispanic | >12 (>16.7) | 28 (38.9) | 31 (43.1) | 0.02 | 0.04 |
| Non-Hispanic | |||||
| Black | <11 (<16.2) | >30 (>44.2) | 27 (39.7) | 0.01 | 0.003 |
| White | 66 (13.0) | 211 (41.5) | 232 (45.6) | −0.1 | −0.04 |
| Insurance status | |||||
| Uninsured | <11 (<26.8) | >11 (>26.8) | 19 (46.3) | NA | NA |
| Private | 65 (17.5) | 152 (40.9) | 155 (41.7) | NA | NA |
| Medicaid | 11 (15.3) | 35 (48.6) | 26 (36.1) | NA | NA |
| Medicare | >13 (>6.4) | 89 (43.8) | 91 (44.8) | NA | NA |
| Income, $ | |||||
| <40 227 | 18 (14.2) | 58 (45.7) | 51 (40.2) | NA | NA |
| 40 227-50 353 | 15 (9.4) | 78 (48.8) | 67 (41.9) | NA | NA |
| 50 354-63 332 | 26 (14.4) | 63 (34.8) | 92 (50.8) | NA | NA |
| ≥63 333 | 40 (17.9) | 97 (43.3) | 87 (38.8) | NA | NA |
| Charlson Comorbidity Index score | |||||
| 0 | 77 (13.6) | 250 (44.2) | 238 (42.1) | −0.02 | −0.06 |
| 1 | 24 (16.2) | 53 (39.2) | 65 (44.6) | 0.02 | 0.04 |
| ≥2 | 3 (25.0) | 2 (16.7) | 7 (58.3) | 0.007 | 0.02 |
| Facility type | |||||
| Academic | 61 (19.7) | 123 (39.8) | 125 (40.5) | NA | NA |
| Nonacademic | 38 (10.2) | 168 (45.0) | 167 (44.8) | NA | NA |
| Nodal status | |||||
| Negative | 28 (14.2) | 86 (43.7) | 83 (42.1) | NA | NA |
| Positive | 53 (16.7) | 119 (37.4) | 146 (45.9) | NA | NA |
| No nodes examined | 18 (9.5) | 97 (51.3) | 74 (39.2) | NA | NA |
| Margin | |||||
| R0 | 75 (17.2) | 178 (40.8) | 183 (42.0) | NA | NA |
| R1/R2 | 11 (9.4) | 50 (42.7) | 56 (47.9) | NA | NA |
| Stage | |||||
| II | 31 (13.8) | 104 (46.2) | 90 (40.0) | 0.01 | −0.04 |
| III | 51 (14.0) | 150 (41.1) | 164 (44.9) | −0.04 | 0.01 |
| IV | 19 (16.2) | 49 (41.9) | 49 (41.9) | 0.03 | 0.03 |
Abbreviations: NA, not applicable; SMD, standardized mean difference.
a
Adjusted for age at diagnosis, sex, race, ethnicity, Charlson Comorbidity Index score, and cancer stage.
b
Considered balanced if the value was less than 0.2.